Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (23 quarters reported)
$184M in Q4 2020 → $1.68B now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Relay Therapeutics Inc | 13.4% | Trimmed 29% | 12,000,000 | $225M |
| Enliven Therapeutics Inc | 9.9% | Unchanged | 3,275,000 | $166M |
| Alkermes PLC | 9.4% | Trimmed 29% | 3,000,000 | $157M |
| Cogent Biosciences Inc | 7.0% | Added 5.6% | 3,050,000 | $118M |
| Amylyx Pharmaceuticals Inc | 6.0% | Unchanged | 5,650,000 | $101M |
| Definium Therapeutics Inc | 5.6% | Unchanged | 2,000,000 | $94.1M |
| Spyre Therapeutics Inc | 4.5% | Trimmed 56% | 846,786 | $75.2M |
| Alto Neuroscience Inc | 4.3% | Unchanged | 2,723,196 | $71.9M |
| Tango Therapeutics Inc | 4.2% | New | 2,250,000 | $70.3M |
| Eyepoint Inc | 3.9% | Added 63% | 4,600,000 | $65.8M |
| Tyra Biosciences Inc | 3.6% | Trimmed 24% | 1,875,000 | $59.9M |
| Damora Therapeutics Inc | 3.0% | Unchanged | 1,939,000 | $50.4M |
| CT Celldex Therapeutics Inc New | 3.0% | Trimmed 50% | 1,350,000 | $50.2M |
| PN Pharvaris N V | 2.9% | Trimmed 26% | 1,425,000 | $49.3M |
| Lb Pharmaceuticals Inc | 2.9% | Unchanged | 1,500,000 | $48.7M |
| Assembly Biosciences Inc | 2.3% | Added 42% | 1,415,000 | $38.9M |
| Editas Medicine Inc | 1.7% | New | 8,889,000 | $28.8M |
| Kymera Therapeutics Inc | 1.7% | Trimmed 67% | 250,000 | $28.7M |
| Perspective Therapeutics Inc | 1.3% | Unchanged | 6,336,782 | $21.6M |
| Century Therapeutics Inc | 1.3% | Unchanged | 8,695,652 | $21.3M |
| Zura Bio Ltd | 1.1% | Unchanged | 3,250,000 | $19.2M |
| Avalo Therapeutics Inc | 1.1% | Added 111% | 1,018,319 | $18.8M |
| Inflarx Nv | 1.0% | New | 7,300,000 | $16.4M |
| An2 Therapeutics Inc | 0.8% | Added 26% | 2,933,680 | $14.2M |
| Nuvalent Inc | 0.7% | Trimmed 88% | 100,000 | $12.4M |
| Sab Biotherapeutics Inc | 0.7% | Trimmed 35% | 2,870,000 | $11.2M |
| Inhibikase Therapeutics Inc | 0.7% | Unchanged | 5,397,488 | $11M |
| Relmada Therapeutics Inc | 0.6% | Added 125% | 1,425,000 | $9.86M |
| Pepgen Inc | 0.5% | Unchanged | 4,475,000 | $8.06M |
| RA Research Alliance Corp Iii | 0.3% | New | 500,000 | $5.35M |
| Helix Acquisition Corp Iii | 0.3% | Unchanged | 500,000 | $5.32M |
| Leonabio Inc | 0.3% | Unchanged | 464,398 | $4.27M |
| Vistagen Therapeutics Inc | 0.0% | New | 2,788,620 | $630K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Spyre Therapeutics Inc | Trimmed | −1,065,594 | −$94.6M | 4.5% |
| Relay Therapeutics Inc | Trimmed | −5,000,000 | −$93.6M | 13.4% |
| Nuvalent Inc | Trimmed | −733,600 | −$90.6M | 0.7% |
| Tango Therapeutics Inc | New | +2,250,000 | +$70.3M | 4.2% |
| Alkermes PLC | Trimmed | −1,200,000 | −$62.9M | 9.4% |
| Kymera Therapeutics Inc | Trimmed | −500,000 | −$57.3M | 1.7% |
| Erasca Inc | Exited | −3,175,000 | −$51.4M | — |
| CT Celldex Therapeutics Inc New | Trimmed | −1,346,616 | −$50.1M | 3.0% |
| Xenon Pharmaceuticals Inc | Exited | −825,000 | −$48M | — |
| Nurix Therapeutics Inc | Exited | −2,275,000 | −$35.3M | — |
Showing the 10 largest of 28 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Terns Pharmaceuticals Inc | Exited | −1,475,000 | −$59.6M | — |
| Xenon Pharmaceuticals Inc | Trimmed | −975,000 | −$56.7M | 2.8% |
| Enliven Therapeutics Inc | Trimmed | −1,417,809 | −$55.6M | 7.4% |
| Oruka Therapeutics Inc | Exited | −1,753,054 | −$53.1M | — |
| Erasca Inc | New | +3,175,000 | +$51.4M | 3.0% |
| Damora Therapeutics Inc | New | +1,939,000 | +$50.2M | 2.9% |
| Protagonist Therapeutics Inc | Exited | −450,000 | −$39.3M | — |
| Definium Therapeutics Inc | New | +2,000,000 | +$37.8M | 2.2% |
| Eyepoint Inc | New | +2,825,000 | +$36.4M | 2.1% |
| Tyra Biosciences Inc | Trimmed | −900,000 | −$34.5M | 5.5% |
Showing the 10 largest of 36 changes.
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Merus N V | Exited | −3,525,000 | −$332M | — |
| Cogent Biosciences Inc | Trimmed | −5,053,155 | −$179M | 5.2% |
| Terns Pharmaceuticals Inc | Trimmed | −4,225,000 | −$171M | 4.0% |
| Agios Pharmaceuticals Inc | Exited | −2,338,287 | −$93.9M | — |
| Nuvalent Inc | Trimmed | −850,000 | −$85.5M | 3.7% |
| Viridian Therapeutics Inc | Exited | −3,200,000 | −$69.1M | — |
| Cidara Therapeutics Inc | Exited | −585,000 | −$56M | — |
| Protagonist Therapeutics Inc | Trimmed | −575,000 | −$50.2M | 2.6% |
| Centessa Pharmaceuticals PLC | Trimmed | −1,850,000 | −$46.3M | 1.7% |
| Xenon Pharmaceuticals Inc | Trimmed | −900,000 | −$40.3M | 5.4% |
Showing the 10 largest of 32 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Cogent Biosciences Inc | Added | +4,938,836 | +$70.9M | 5.1% |
| Cidara Therapeutics Inc | Trimmed | −590,000 | −$56.5M | 2.7% |
| Amylyx Pharmaceuticals Inc | New | +4,075,478 | +$55.4M | 2.7% |
| SR Scholar Rock Hldg Corp | Exited | −1,450,000 | −$51.4M | — |
| Soleno Therapeutics Inc | Added | +740,000 | +$50M | 4.5% |
| Terns Pharmaceuticals Inc | New | +5,700,000 | +$42.8M | 2.1% |
| Viridian Therapeutics Inc | Trimmed | −1,675,000 | −$36.1M | 3.4% |
| Assembly Biosciences Inc | New | +1,000,000 | +$25.6M | 1.2% |
| Lb Pharmaceuticals Inc | New | +1,500,000 | +$23.7M | 1.2% |
| MM Mind Medicine Mindmed Inc | Trimmed | −1,775,000 | −$20.9M | 1.9% |
Showing the 10 largest of 28 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Vaxcyte Inc | Exited | −1,650,000 | −$62.3M | — |
| Protagonist Therapeutics Inc | New | +1,075,000 | +$59.4M | 4.2% |
| Cidara Therapeutics Inc | New | +1,175,000 | +$57.2M | 4.0% |
| Merus N V | Trimmed | −947,840 | −$49.9M | 13.1% |
| Cogent Biosciences Inc | Trimmed | −6,581,652 | −$47.3M | 1.2% |
| Relay Therapeutics Inc | New | +13,350,000 | +$46.2M | 3.3% |
| Soleno Therapeutics Inc | Trimmed | −540,000 | −$45.2M | 3.6% |
| Vera Therapeutics Inc | Trimmed | −1,761,782 | −$41.5M | 1.3% |
| Nuvalent Inc | Trimmed | −480,000 | −$36.6M | 7.4% |
| Kymera Therapeutics Inc | New | +750,000 | +$32.7M | 2.3% |
Showing the 10 largest of 30 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Agios Pharmaceuticals Inc | New | +2,185,000 | +$64M | 4.7% |
| CT Celldex Therapeutics Inc New | New | +3,200,000 | +$58.1M | 4.3% |
| Soleno Therapeutics Inc | Trimmed | −375,000 | −$26.8M | 6.1% |
| SR Scholar Rock Hldg Corp | Added | +795,000 | +$25.6M | 4.1% |
| Merus N V | Added | +598,658 | +$25.2M | 13.9% |
| Solid Biosciences Inc | New | +5,825,000 | +$21.6M | 1.6% |
| Nuvalent Inc | Added | +233,400 | +$16.6M | 9.7% |
| Viridian Therapeutics Inc | Added | +1,200,000 | +$16.2M | 3.6% |
| Vera Therapeutics Inc | Added | +603,182 | +$14.5M | 4.5% |
| Xenon Pharmaceuticals Inc | Trimmed | −415,000 | −$13.9M | 5.7% |
Showing the 10 largest of 25 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Vaxcyte Inc | Added | +705,000 | +$57.7M | 9.7% |
| CT Celldex Therapeutics Inc New | Exited | −1,618,937 | −$55M | — |
| Nuvalent Inc | Added | +681,600 | +$53.4M | 9.3% |
| Perspective Therapeutics Inc | Exited | −3,350,000 | −$44.7M | — |
| SR Scholar Rock Hldg Corp | New | +950,000 | +$41.1M | 3.0% |
| Kura Oncology Inc | Exited | −1,800,000 | −$35.2M | — |
| Rhythm Pharmaceuticals Inc | Exited | −650,000 | −$34.1M | — |
| Arvinas Inc | Exited | −1,200,000 | −$29.6M | — |
| MM Mind Medicine Mindmed Inc | Trimmed | −3,691,575 | −$25.7M | 2.2% |
| Nurix Therapeutics Inc | Added | +1,350,000 | +$25.4M | 4.1% |
Showing the 10 largest of 31 changes.
quarter ended September 30, 2024 · filed November 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Nuvalent Inc | Trimmed | −547,756 | −$56M | 6.0% |
| Vaxcyte Inc | Trimmed | −385,000 | −$44M | 6.6% |
| Alkermes PLC | Added | +1,525,000 | +$42.7M | 5.1% |
| Nurix Therapeutics Inc | New | +1,650,000 | +$37.1M | 2.3% |
| Oruka Therapeutics Inc | New | +1,369,714 | +$33.6M | 2.1% |
| Rhythm Pharmaceuticals Inc | Trimmed | −575,000 | −$30.1M | 2.1% |
| Cogent Biosciences Inc | Trimmed | −2,198,070 | −$23.7M | 5.1% |
| Centessa Pharmaceuticals PLC | New | +1,350,000 | +$21.6M | 1.3% |
| Immunovant Inc | Exited | −750,990 | −$19.8M | — |
| Perspective Therapeutics Inc | Trimmed | −1,307,345 | −$17.5M | 2.8% |
Showing the 10 largest of 28 changes.
Loading...
